Previous 10 | Next 10 |
REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in...
REHOVOT, Israel, and BRIDGEWATER, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today annou...
REHOVOT, Israel and BRIDGEWATER, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in...
Foamix Pharmaceuticals (FOMX) Q4 2018 Results Earnings Conference Call March 01, 2019, 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commer...
Foamix Pharmaceuticals ( FOMX ) FY results : Revenues: $3.6M (-2.7%). More news on: Foamix Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Foamix Pharmaceuticals (NASDAQ: FOMX ): FY GAAP EPS of -$1.70. More news on: Foamix Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietar...
Thinly traded micro cap Foamix Pharmaceuticals (NASDAQ: FOMX ) is up 4% premarket on average volume following its announcement of results from the open-label Phase 3 FX2016-13 safety study evaluating up to a year's treatment with FMX103 in patients with moderate-to-severe pa...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapi...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapi...
News, Short Squeeze, Breakout and More Instantly...
Foamix Pharmaceuticals Ltd. Company Name:
FOMX Stock Symbol:
NASDAQ Market:
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address ...
REHOVOT, Israel, BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and...